APP13007
Inflammation and pain after ocular surgery
ApprovedCommercialized (licensed)
Key Facts
Indication
Inflammation and pain after ocular surgery
Phase
Approved
Status
Commercialized (licensed)
Company
About Formosa Pharmaceuticals
A clinical-stage biotech company developing ophthalmology and oncology therapies using its proprietary APNT® nanoparticle platform and ADC technology.
View full company profile